Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Synairgen plc
The company is running out of chances for its inhaled interferon therapy after a Phase III study failed to show benefits for hospitalized COVID-19 patients.
Global research and development for preventative vaccines and therapeutics to treat COVID-19 have progressed at a rapid pace. Still, key issues remain and to the dampen the effects of virus in 2022, even greater collaboration is needed.
Coronavirus Notebook: Valneva Vaccine To Begin EU Rolling Review, Synairgen Reports Progress With Inhaled IFN-Beta
The European Parliament is pushing for more of a say in how Europe’s new emergency response authority, HERA, deals with R&D and procurement of vaccines and therapies in times of health crises. NRx Therapeutics says it will continue to seek US approval of aviptadil for COVID-19.
SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.
- Drug Discovery Tools
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Synairgen Research Ltd